{"summary":"Alex M. Chen is the co-founder and CEO of Crystal Pharmatech, a specialized CRO\/CDMO that excels in crystal form and formulation services for biotech and pharmaceutical companies worldwide. With over 13 years of experience in leading and growing a global CDMO business, Alex has a proven track record of delivering world-class solutions for complex and challenging molecules. He holds over 100 patents and 20 publications in the field of solid-state research, polymorph and co-crystal screening, chiral resolution, and nanoparticle technology for drug delivery.\n\nAs a visionary and entrepreneurial leader, Alex guides a skilled team of around 250 professionals across three strategically located R&D centers in China, USA, and Canada. He oversees the development and implementation of the innovative Molecule-Material-Medicine (MMM) approach, which optimizes the crystals and formulations for clients' molecules, pursuing unparalleled outcomes. Alex is also the co-founder of the New Drug Founders' Club (NDFC), one of China's largest non-profit organizations for biotech founders, with over 500 members, including over 50% of publicly listed biotech company founders in China. Alex's mission is to foster a vibrant and collaborative ecosystem for biotech innovation and development.","lastName":"Chen","objectUrn":"urn:li:member:42543843","geoRegion":"Princeton, New Jersey, United States","fullName":"Alex Chen","firstName":"Alex","currentPositions":[{"companyName":"New Drug Founders Club","description":"New Drug Founders' Club (NDFC) is one of China's largest non-profit organizations for Biotech Founders. The NDFC has experienced remarkable growth and boasts a membership of over 500 esteemed entrepreneurs, including biotech founders, CRO\/CDMO founders, and venture capital managing directors. Over 50% of publicly listed biotech company founders in China have chosen to join the esteemed ranks of the NDFC, highlighting its significance and ability to attract prominent figures in the biotech industry.","title":"Co-Founder and Executive Committee Member","tenureAtCompany":{"numYears":9,"numMonths":3},"startedOn":{"month":3,"year":2015}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1701898416286?e=1723075200&v=beta&t=sMBZOgioM5gj_1lnC08VDvNO0eNUsepwrCblDzBv71M","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1701898416286?e=1723075200&v=beta&t=mXsTyJJgoknfpOh2jkElBmpQyu_CTekXd7k-d1rCgCA","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1701898416286?e=1723075200&v=beta&t=H-39kWZhbgpiPRH-liQVfUudUtOoBhX1QJQo_P794mI","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1701898416286?e=1723075200&v=beta&t=ETn65AlaKTQ2yrcBqCPV0-SuUB5ZUAbZomApbZA9ZAc","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/D4D03AQHfcg8f6XgCPQ\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{"websites":[{"$anti_abuse_annotations":[{"attributeId":97,"entityId":19,"sourceUrn":"urn:li:member:42543843"},{"attributeId":48,"entityId":19,"sourceUrn":"urn:li:member:42543843"}],"category":"COMPANY","dataSource":"LINKEDIN","url":"http:\/\/www.crystalpharmatech.com"}],"socialHandles":[{"type":"WECHAT","name":"\u9648\u654f\u534e-\u82cf\u5dde\u6676\u4e91","dataSource":"LINKEDIN"}]},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"year":2009},"degree":"Ph.D.","eduId":46329640,"schoolUrn":"urn:li:fs_salesSchool:15100377","school":"urn:li:fs_salesSchool:15100377","fieldsOfStudy":["Chemistry"],"schoolName":"Rutgers University - Newark","startedOn":{"year":2004}},{"endedOn":{"year":2002},"degree":"M.S.","eduId":53804112,"schoolUrn":"urn:li:fs_salesSchool:6464","school":"urn:li:fs_salesSchool:6464","fieldsOfStudy":["Chemistry"],"startedOn":{"year":2000}},{"endedOn":{"year":2000},"degree":"B.S.","eduId":31157622,"schoolUrn":"urn:li:fs_salesSchool:20289","school":"urn:li:fs_salesSchool:20289","fieldsOfStudy":["Chemistry"],"startedOn":{"year":1996}},{"endedOn":{"year":1996},"schoolName":"Zhejiang Jinhua No. 1 High School","startedOn":{"year":1993},"eduId":46622246}],"skills":[{"numOfEndorsement":1,"name":"Business Development"},{"numOfEndorsement":1,"name":"PROTAC Formulation Development"},{"numOfEndorsement":1,"name":"Nanomilling Formulation"},{"numOfEndorsement":0,"name":"Microed"},{"numOfEndorsement":0,"name":"Single Crystal X-ray Diffraction"},{"numOfEndorsement":0,"name":"Clinical Supplies"},{"numOfEndorsement":0,"name":"CMC development"},{"numOfEndorsement":0,"name":"Chemistry, Manufacturing, and Controls (CMC)"},{"numOfEndorsement":0,"name":"Preformulation"},{"numOfEndorsement":0,"name":"Salt and Cocrystal Screening"},{"numOfEndorsement":0,"name":"Minitab"},{"numOfEndorsement":0,"name":"Formulation Development and Manufacturing"},{"numOfEndorsement":0,"name":"Amorphous Solid Dispersion"},{"numOfEndorsement":0,"name":"LNP Formulation"},{"numOfEndorsement":0,"name":"Chiral resolution"},{"numOfEndorsement":0,"name":"Solid Oral Dosage Forms"},{"numOfEndorsement":0,"name":"Polymorph Screening"},{"numOfEndorsement":0,"name":"Solid State Characterization"},{"numOfEndorsement":96,"name":"Chemistry"},{"numOfEndorsement":65,"name":"Analytical Chemistry"},{"numOfEndorsement":34,"name":"Drug Delivery"},{"numOfEndorsement":24,"name":"Characterization"},{"numOfEndorsement":53,"name":"R&D"},{"numOfEndorsement":9,"name":"Nanotechnology"},{"numOfEndorsement":17,"name":"Purification"},{"numOfEndorsement":36,"name":"Formulation"},{"numOfEndorsement":6,"name":"Cell"},{"numOfEndorsement":3,"name":"Crystallization"},{"numOfEndorsement":10,"name":"Nanoparticles"},{"numOfEndorsement":6,"name":"Dissolution"},{"numOfEndorsement":18,"name":"Pharmaceutics"},{"numOfEndorsement":9,"name":"Cancer"},{"numOfEndorsement":2,"name":"High Throughput Screening"},{"numOfEndorsement":17,"name":"Technology Transfer"},{"numOfEndorsement":24,"name":"Pharmaceutical Industry"},{"numOfEndorsement":7,"name":"CRO"}],"pronoun":"He\/Him","numOfConnections":4178,"patents":[],"headline":"Co-Founder, CEO @ Crystal Pharmatech | CRO\/CDMO, Solid-State Research, Formulation Development and Manufacturing","courses":[],"certifications":[],"memberBadges":{"premium":true,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/crystalpharmatech","organizations":[],"location":"Princeton, New Jersey, United States","publications":[{"name":"Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA","publishedOn":{"month":12,"day":1,"year":2011},"publisher":"Journal of drug targeting","url":"https:\/\/www.tandfonline.com\/doi\/abs\/10.3109\/1061186X.2011.622404","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAtuvYUBSQxdQrscEh-mciXru-nHMhOB5WA,NAME_SEARCH,AMnl)"}]},{"name":"Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug resistant cancer cells","publishedOn":{"month":12,"day":1,"year":2009},"publisher":"Small (Weinheim an der Bergstrasse, Germany)","url":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2833276\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYlvGAB4JgGo9nHHc6GlJfO9F0_1BBQOgw,NAME_SEARCH,YZzR)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARCXlIBQjWaoewEwTdvV8O-ZCCT8QSQecc,NAME_SEARCH,4jz5)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAM1yagBvpJYic0Fp3S9GDJMUDG20nCrVkU,NAME_SEARCH,jhyG)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAtuvYUBSQxdQrscEh-mciXru-nHMhOB5WA,NAME_SEARCH,AMnl)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTOEBAHs7MI5QTdsSMwM2eDVQSUmik5k,NAME_SEARCH,UhmC)"}]},{"name":"DNA and carbon nanotubes as medicine","publishedOn":{"month":4,"day":30,"year":2010},"publisher":"Advanced drug delivery reviews","url":"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0169409X10000761","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAtuvYUBSQxdQrscEh-mciXru-nHMhOB5WA,NAME_SEARCH,AMnl)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTOEBAHs7MI5QTdsSMwM2eDVQSUmik5k,NAME_SEARCH,UhmC)"}]},{"name":"Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor","publishedOn":{"month":2,"day":5,"year":2008},"publisher":"US Patent","url":"https:\/\/patents.google.com\/patent\/US7326708\/en","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAI-vP8BQ4WkfE459uCBjiSEaaGSuN_g_eo,NAME_SEARCH,Q7DQ)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMyZ6wBjuQZzZGAkeTkUWUegVI8mXe6jH8,NAME_SEARCH,hm3P)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAANAlZEBJUT1XWGpes5OPVzPdRe8LCp1_ZQ,NAME_SEARCH,rpbY)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAK5VlEByd4HbyJNQYGzMtajN7mAwE4OeB4,NAME_SEARCH,C_Gq)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAALqM4cBRnRnEhilNI2qydpfhu2L8XdcCjE,NAME_SEARCH,qy9J)"}]},{"name":"Enantioenrichment by crystallization","publishedOn":{"month":3,"day":24,"year":2008},"publisher":"Organic Process Research & Development","url":"https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/op700239a","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAO4f-MBYSHP2IiLYflmzbyEKe6IA-77wGY,NAME_SEARCH,oXF-)"}]},{"name":"Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity","publishedOn":{"month":5,"day":18,"year":2007},"publisher":"Organic process research & development","url":"https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/op700026n","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA-68C8B828x5orkQSOzGRAiaC7NZqEOuvk,NAME_SEARCH,EkWI)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAGDCLABr0Mt9jWZIqaid719mwxBpTADfjU,NAME_SEARCH,7V4n)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAACfdWABuPdM53Gvf0tczEUfggQkuO9IL98,NAME_SEARCH,IG0w)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAbOZBUBrQKbLe3t1GcODMQkbAGAa6i9Wco,NAME_SEARCH,U9jk)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAEfgr0Bu6PXgg_WYUaPZlv6AHAKt6Scy3I,NAME_SEARCH,fp78)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAUl7KMBMZENVLNVrVcvBisuCLCkIAZcm5Q,NAME_SEARCH,_zXh)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAEjdbABA5N_dGvZr8coIdeIftlJ8N2kjWA,NAME_SEARCH,nkv7)"}]},{"name":"Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid","publishedOn":{"month":1,"day":1,"year":2007},"publisher":"Chemical communications","url":"https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2007\/cc\/b612353h\/unauth","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAADqpCQBvfmeD2_QgQM8uUnbV6c8rvrj0Co,NAME_SEARCH,Ea6q)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAIF4rgBRFguGmhBcZsE7c7DqtVqzTa4QJk,NAME_SEARCH,756X)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAALqM4cBRnRnEhilNI2qydpfhu2L8XdcCjE,NAME_SEARCH,qy9J)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAGCNhEBII5O6On2HIBcHw8VjkxOLyx2-V4,NAME_SEARCH,mdEj)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAPTNikBn-EtASmEPzhgRa-tR_bNPICP27o,NAME_SEARCH,nHaD)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABG2YNgBuCJ18e12hwCcmYaumpygzpbj3g4,NAME_SEARCH,-pwB)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKa9x0Bj9ITE-SBA91UgKzqfBu-BhntQkk,NAME_SEARCH,d-OL)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAO4f-MBYSHP2IiLYflmzbyEKe6IA-77wGY,NAME_SEARCH,oXF-)"}]},{"name":"Labile catalytic packaging of DNA\/siRNA: control of gold nanoparticles \u201cout\u201d of DNA\/siRNA complexes","publishedOn":{"month":7,"day":27,"year":2010},"publisher":"ACS nano","url":"https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/nn901796n","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAtuvYUBSQxdQrscEh-mciXru-nHMhOB5WA,NAME_SEARCH,AMnl)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARCXlIBQjWaoewEwTdvV8O-ZCCT8QSQecc,NAME_SEARCH,4jz5)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTOEBAHs7MI5QTdsSMwM2eDVQSUmik5k,NAME_SEARCH,UhmC)"}]},{"name":"Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor","publishedOn":{"month":1,"day":25,"year":2007},"publisher":"US","url":"https:\/\/patents.google.com\/patent\/US20070021430A1\/en","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAALqM4cBRnRnEhilNI2qydpfhu2L8XdcCjE,NAME_SEARCH,qy9J)"}]},{"name":"The electronic role of DNA-functionalized carbon nanotubes: Efficacy for in situ polymerization of conducting polymer nanocomposites","publishedOn":{"month":6,"day":25,"year":2008},"publisher":"Journal of the American Chemical Society","url":"https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/ja7112189","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTTEBzLMtnw5ThCsGPa_Hz42ySw--l40,NAME_SEARCH,oExU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTOEBAHs7MI5QTdsSMwM2eDVQSUmik5k,NAME_SEARCH,UhmC)"}]},{"name":"Oligodeoxynucleotide nanostructure formation in the presence of polypropyleneimine dendrimers and their uptake in breast cancer cells","publishedOn":{"month":10,"day":20,"year":2006},"publisher":"Nanotechnology","url":"https:\/\/iopscience.iop.org\/article\/10.1088\/0957-4484\/17\/21\/027\/meta","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTOEBAHs7MI5QTdsSMwM2eDVQSUmik5k,NAME_SEARCH,UhmC)"}]},{"name":"Drying an organic monohydrate: crystal form instabilities and a factory-scale drying scheme to ensure monohydrate preservation","publishedOn":{"month":7,"day":16,"year":2004},"publisher":"Organic process research & development","url":"https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/op049956a","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAI-vP8BQ4WkfE459uCBjiSEaaGSuN_g_eo,NAME_SEARCH,Q7DQ)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAALqM4cBRnRnEhilNI2qydpfhu2L8XdcCjE,NAME_SEARCH,qy9J)"}]},{"name":"Design of experiments utilization to map the processing capabilities of a micro-spray dryer: particle design and throughput optimization in support of drug discovery","publishedOn":{"month":2,"day":1,"year":2013},"publisher":"Pharmaceutical Development and Technology","url":"https:\/\/www.tandfonline.com\/doi\/abs\/10.3109\/10837450.2011.646424","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAEOQtABn2i-BPyje8225vZkv5QHsrqfg3A,NAME_SEARCH,b5LC)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAPF4rsBhDCKR2InlKluUSexPi6oa93zLSA,NAME_SEARCH,zqWe)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAABBJtwBxzltNY6hV8Gnf9ofsB8HCmdkL_U,NAME_SEARCH,8DSq)"}]},{"name":"Crystallization\u2010based separation of enantiomers","publishedOn":{"month":9,"day":27,"year":2013},"publisher":"Stereoselective synthesis of drugs and natural products","url":"https:\/\/scholar.google.com\/citations?view_op=view_citation&hl=en&user=WvdafhgAAAAJ&citation_for_view=WvdafhgAAAAJ:aqlVkmm33-oC","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAO4f-MBYSHP2IiLYflmzbyEKe6IA-77wGY,NAME_SEARCH,oXF-)"}]},{"name":"Purification of partially resolved enantiomeric mixtures with the guidance of ternary phase diagram","publishedOn":{"month":3,"day":24,"year":2008},"publisher":"Organic Process Research & Development","url":"https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/op7002387","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAO4f-MBYSHP2IiLYflmzbyEKe6IA-77wGY,NAME_SEARCH,oXF-)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAALqM4cBRnRnEhilNI2qydpfhu2L8XdcCjE,NAME_SEARCH,qy9J)"}]},{"name":"Conformational dynamics of estrogen receptors \u03b1 and \u03b2 as revealed by intrinsic tryptophan fluorescence and circular dichroism","publishedOn":{"month":10,"day":1,"year":2005},"publisher":"Journal of molecular endocrinology","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTOEBAHs7MI5QTdsSMwM2eDVQSUmik5k,NAME_SEARCH,UhmC)"}]},{"name":"Highly aligned ribbon-shaped Pd nanoparticle assemblies by spontaneous organization","publishedOn":{"month":5,"day":31,"year":2007},"publisher":"The Journal of Physical Chemistry C","url":"https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/jp0706937","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAtuvYUBSQxdQrscEh-mciXru-nHMhOB5WA,NAME_SEARCH,AMnl)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABfA7LsBxxeSE6Y31lrn6OTFDJICrmJUXXs,NAME_SEARCH,aKBD)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTOEBAHs7MI5QTdsSMwM2eDVQSUmik5k,NAME_SEARCH,UhmC)"}]},{"name":"Nanotechnology in Nonviral Gene Delivery","publishedOn":{"month":1,"day":1,"year":2005},"publisher":"Nanotechnology","url":"https:\/\/studfile.net\/preview\/395630\/page:11\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAlGTOEBAHs7MI5QTdsSMwM2eDVQSUmik5k,NAME_SEARCH,UhmC)"}]},{"name":"Sweet pharmaceutical salts of stanozolol with enhanced solubility and physical stability","publishedOn":{"month":12,"day":7,"year":2016},"publisher":"CrystEngComm","url":"https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2016\/ce\/c6ce01876a\/unauth","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAMwVQMBgLBdkZ0TbyVkVOY0uPSlJEHXBwk,NAME_SEARCH,2yFS)"}]},{"name":"Electrodeposition of diamondlike carbon films on nickel substrates","publishedOn":{"month":7,"day":1,"year":2003},"publisher":"Journal of Materials Research","url":"https:\/\/link.springer.com\/article\/10.1557\/JMR.2003.0215","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJKuMBKvpGdv1sU5QW_Z9Dso24LkC-oSA,NAME_SEARCH,JtSF)"}]}],"positions":null,"posts":[{"createdAt":1712184060000,"insightId":"fcb303ba-8226-48f8-9db7-66b52784b627","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":37}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7181420468606803968","threadUrn":"urn:li:activity:7181420468606803968","reactionsCount":37,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7181420467268829186","message":{"attributes":[{"start":76,"length":18,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1213360"}}},{"start":115,"length":60,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:77580143"}}},{"start":592,"length":6,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:merck"}}},{"start":599,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:crystalpharmatech"}}},{"start":618,"length":23,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:formulationdevelopment"}}}],"text":"Congratulations to the Merck team for their outstanding success. Meanwhile, Crystal Pharmatech's formulation team (Crystal Formulation Services, a member of Crystal Pharmatech) is engaging in substantive work, partnering with select biotechs to advance oral dosage formulations for peptides, including notable efforts on macrocyclic peptides and leading-edge GLP-1R and GCGR dual agonist programs. For those with peptide pipelines in need of expert collaboration in solid oral dosage formulation development, we're more than willing to tackle these challenging and promising areas together.\n\n#Merck #CrystalPharmatech #FormulationDevelopment"},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D5610AQFi9_tadwV9Hg\/image-shrink_1280\/0\/1712176680374?e=1717977600&v=beta&t=a3toIsvF97xlu7e7o2taLGHwO2nagsgG_GWvXWYElDg","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D5610AQFi9_tadwV9Hg\/image-shrink_1280\/0\/1712176680374?e=1717977600&v=beta&t=a3toIsvF97xlu7e7o2taLGHwO2nagsgG_GWvXWYElDg"}]},"description":"Merck\u2019s macrocyclic PCSK9 protein-protein interaction (PPI) inhibitor, MK-0616, is a once-daily PCSK9-lowering and LDL-cholesterol-lowering small molecule that has recently demonstrated antibody-like...","resolvedUrl":"https:\/\/drughunters.com\/3PLxTEk","title":"MK-0616"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7181389499468247041","message":{"attributes":[{"start":64,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/gmYxYD43"}}},{"start":135,"length":5,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1486"}}},{"start":887,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/gmYxYD43"}}}],"text":"MK-0616: \u201cI Was Told.. an Oral PCSK9 Inhibitor is Impossible\u201d | https:\/\/lnkd.in\/gmYxYD43\n\n-2023 Molecule of the Year Nominee (#1\/10)-\n\nMerck's macrocyclic PCSK9 protein-protein interaction (PPI) inhibitor, MK-0616, is a once-daily PCSK9-lowering and LDL-cholesterol-lowering small molecule that has recently demonstrated antibody-like efficacy as an oral agent in the clinic. \n\nThe program highlights numerous technical achievements at the forefront of modern drug discovery, from mRNA display screening to the use of lipidic permeation enhancer formulations, and will set a standard for modern \u201cclassics in drug discovery\u201d for some time. \n\nIn this case study, we review the drug discovery campaign leading to MK-0616 from hit-finding to clinical development, highlighting why this molecule continues to be a \u201cbig deal\u201d and a standard for modern \u201cclassics in drug discovery.\u201d\n\nArticle | https:\/\/lnkd.in\/gmYxYD43\n"},"entityUrn":"urn:li:share:7181389499468247041"},"entityUrn":"urn:li:share:7181420467268829186"}}},{"createdAt":1712171640000,"insightId":"70439e7d-e389-43b8-9065-9d7beef19a65","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":15}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7181368554405933056","threadUrn":"urn:li:ugcPost:7181368554405933056","reactionsCount":15,"commentsCount":2,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7181368554405933056","message":{"attributes":[{"start":20,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:6747058"}}},{"start":54,"length":8,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1406"}}},{"start":310,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:formulation"}}},{"start":323,"length":22,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:solubilityenhancement"}}},{"start":346,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:novartis"}}},{"start":356,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:crystalpharmatech"}}}],"text":"Excited to hear Dr. Sudhakar Garad's perspective from Novartis on the latest formulation strategies and technologies for enhancing the solubility and bioavailability of insoluble compounds. Join us as we delve into innovative formulation solutions for one of the pharmaceutical industry's pressing challenges. #Formulation #SolubilityEnhancement #Novartis #CrystalPharmatech"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"Formulation Forum: Episode 1"},"mediaType":"VIDEO","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4D05AQGoptJsgxwgGw\/feedshare-thumbnail_720_1280\/0\/1712165287715?e=1717977600&v=beta&t=uZnYQjcBjBKO2JyxBEb8DxBMY6fy1V7UgIdSkSfqSUM"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7181341713565638656","message":{"attributes":[{"start":181,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:6747058"}}},{"start":266,"length":8,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1406"}}},{"start":375,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/dE2h2CYu"}}},{"start":403,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:crystalpharmatech"}}},{"start":422,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:formulationforum"}}},{"start":440,"length":22,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharmaceuticalscience"}}},{"start":463,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cmc"}}},{"start":468,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biotech"}}},{"start":477,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopemnt"}}},{"start":494,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:formulation"}}},{"start":507,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharma"}}},{"start":515,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:research"}}},{"start":525,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:technology"}}},{"start":537,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:api"}}},{"start":542,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cro"}}},{"start":547,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cdmo"}}}],"text":"\ud83d\udce2 April 17th at 2pm: Join us for the first webinar of the Crystal Pharmatech Formulation Forum:\n\u201cOvercoming Poor Solubility and Dissolution of Insoluble Molecules\u201d.\n\u00a0\nPresented by Sudhakar Garad, Ph.D., Global Head of Chemical and Pharmaceutical Profiling Group at Novartis.\n\u00a0\nThis content is only available during the live webinar and Q&A session!\n\u00a0\n\ud83d\udcc5 Register to attend: https:\/\/lnkd.in\/dE2h2CYu \n\u00a0\n#CrystalPharmatech #FormulationForum #PharmaceuticalScience #CMC #Biotech #DrugDevelopemnt #Formulation #Pharma #Research #Technology #API #CRO #CDMO"},"entityUrn":"urn:li:ugcPost:7181341713565638656"},"entityUrn":"urn:li:ugcPost:7181368554405933056"}}},{"createdAt":1711489200000,"insightId":"584fa731-6aaa-46b3-b410-0964c377af76","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":8}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7178506016278368256","threadUrn":"urn:li:ugcPost:7178506016278368256","reactionsCount":8,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7178506016278368256","message":{"attributes":[{"start":127,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:crystalpharmatech"}}},{"start":174,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biotechtuesday"}}}],"text":"Will you be in Boston on April 2nd? If so, don't miss the chance to attend the engaging Formulation panel discussion hosted by #CrystalPharmatech, as well as the exceptional #BiotechTuesday networking event, where you'll connect with hundreds of new drug discovery and development professionals."},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"Biotech Forum April 2nd in Cambridge, MA"},"mediaType":"VIDEO","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4D05AQGzrSHx8nkMVw\/feedshare-thumbnail_720_1280\/0\/1711471297248?e=1717977600&v=beta&t=BsWBvFCiy3IZ4QEaDkmWhoPJEUlJxxcP4-8G0bLUGxs"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7178430905164652544","message":{"attributes":[{"start":385,"length":14,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1941491"}}},{"start":488,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/dzEb6jVu"}}},{"start":515,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:48903047"}}},{"start":530,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:94993229"}}},{"start":544,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:19871330"}}},{"start":558,"length":11,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:14392128"}}},{"start":570,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:18694930"}}},{"start":585,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:crystalpharmatech"}}},{"start":604,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biotechtuesday"}}},{"start":620,"length":13,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharmaevents"}}},{"start":634,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biotechboston"}}},{"start":649,"length":22,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharmaceuticalscience"}}},{"start":672,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cmc"}}},{"start":677,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biotech"}}},{"start":686,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopment"}}},{"start":703,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:research"}}},{"start":713,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:technology"}}},{"start":725,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:api"}}},{"start":730,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cro"}}},{"start":735,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cdmo"}}}],"text":"How do leading experts across the industry approach CMC projects? Join us next Tuesday, April 2nd, in Cambridge, MA to find out.\n\u00a0\nA panel of esteemed CMC experts will use a redacted project as a live case study discussion, breaking down various approaches to formulation development and CMC best practices.\n\u00a0\nThis presentation includes happy hour refreshments and leads directly into BiotechTuesday\u2019s networking event with hundreds of industry colleagues.\n\u00a0\nRegister for the discussion: https:\/\/lnkd.in\/dzEb6jVu\n\u00a0\nRobert Wenslow Steven Mennen Magali Hickey Eric Simone Ray Forslund\n\u00a0\n#CrystalPharmatech #BiotechTuesday #PharmaEvents #BiotechBoston #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Research #Technology #API #CRO #CDMO"},"entityUrn":"urn:li:ugcPost:7178430905164652544"},"entityUrn":"urn:li:ugcPost:7178506016278368256"}}},{"createdAt":1714006560000,"insightId":"1b7c3622-8eea-4e2e-890b-2d7cbdb7b72c","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7184257487498354689,7189064672879292416)","threadUrn":"urn:li:ugcPost:7184257487498354689","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations, Prabha!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7184257487498354689"}}},{"createdAt":1713474420000,"insightId":"071956bd-143c-4657-a795-6681895b609d","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7186831113992949760,7186832778368331778)","threadUrn":"urn:li:activity:7186831113992949760","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations to the TCG GreenChem Team!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7186831113992949760"}}},{"createdAt":1712693700000,"insightId":"e3c371ae-a6ba-4136-89af-b3e186a2bdb9","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7183326865581846528,7183558194525294593)","threadUrn":"urn:li:ugcPost:7183326865581846528","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Firouz!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7183326865581846528"}}},{"createdAt":1712077440000,"insightId":"c0e16414-9c51-499c-959c-60ae05573d80","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7180959685615710208,7180973272858062850)","threadUrn":"urn:li:activity:7180959685615710208","reactionsCount":2,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Thank you so much, Ray and Syner-G Biopharma, for your participation. We eagerly anticipate the panel discussion."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7180959685615710208"}}},{"createdAt":1712014920000,"insightId":"d803db1f-fd28-483d-844c-2fb7be076e15","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7180653648740327425,7180711163188412416)","threadUrn":"urn:li:activity:7180653648740327425","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations, Wenshe!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7180653648740327425"}}},{"createdAt":1711107780000,"insightId":"1ee3d3a4-479a-49c9-92c6-fbd8f9364548","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7176620883124400128,7176906410880860160)","threadUrn":"urn:li:activity:7176620883124400128","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats on the great partnership between Neurophth and CATUG!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7176620883124400128"}}}]}